Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly to support hospitals facing difficulties with supplies of medicinal products used in the treatment of COVID-19 patients. In addition, given the specific context of use of these medicinal products, the FAMHP has ensured close monitoring of adverse reactions.
News FAMHP
There are 84 result(s) found based on your search criteria
31-40 from 84 result(s)
Coronavirus and the fight led by the FAMHP: the FAMHP facilitates and supports the development of COVID-19 treatments and vaccines
Since the start of the coronavirus pandemic, the FAMHP teams have devoted a lot of resources to monitoring and supporting clinical research on COVID-19. Here is an overview of the measures implemented by the FAMHP.
Limited availability of Gardasil 9 vaccine: updated recommendations for prescribers
Due to a worldwide increase in demand for the Gardasil 9 vaccine, used to prevent Human Papillomavirus (HPV), stocks of this vaccine are currently limited in Belgium. This limited availability has been extended and should continue until September 2020. The Federal Agency for Medicines and Health Products (FAMHP) has updated the recommendations for prescribers.
Coronavirus and the fight led by the FAMHP: rigorous work to ensure each patient receives the treatment they need
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly to support hospitals and pharmacies facing difficulties in securing supplies of medicinal products. Here is an overview of the measures put in place by the FAMHP to guarantee stocks of medicinal products in Belgium.
New downward trend in the consumption of antibiotics in animal husbandry in Belgium
The new BelVet-SAC report which contains an overview of the use of antibiotics in veterinary medicine is available. The 2019 results confirm the trends of previous years with consumption down 7.8% for mg of active substance/kg of biomass compared to last year. Compared to the 2011 reference year, the use of antibiotics in veterinary medicine has decreased by 40.3%.
Coronavirus : first COVID-19 vaccine trial authorized in Belgium
The Federal Agency for Medicines and Health Products (FAMHP) has authorized the first clinical trial evaluating a vaccine against COVID-19 in Belgium. This is the candidate vaccine from the German biotech firm CureVac.
Webinar on the use of antibiotics and antibiotic resistance in animals: 2019 results, what is the outlook after 2020?
On Monday 22 June 2020 AMCRA, FASFC, FAMHP and FPS Public Health will host a webinar presenting the latest results on the use of antibiotics in animals and the fight against antimicrobial resistance.
Web portal - updates to the “My company” and “My activities” applications
In anticipation of the European regulations on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), the FAMHP has updated the “My company” and “My activities” applications in its web portal.
Coronavirus: extension and relaxing of measures taken by the FAMHP to avoid medicinal product shortages
On 1 April 2020, the FAMHP took steps to avoid a shortage of medicinal products. Some of these measures are to be further extended by one month, while others have been lifted.
Coronavirus: hydroxychloroquine: off-label use strongly discouraged and new benefit-risk assessment for clinical trials
The new COVID-19 treatment recommendations from Sciensano strongly advise against any off-label use of hydroxychloroquine outside of a clinical trial. Applicants for ongoing clinical trials must also update their benefit-risk assessment and demonstrate to the FAMHP that their risk reduction strategies during the trial are sufficiently adequate.